These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18569774)

  • 21. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High societal costs of brain diseases. Extremely small resources allocated to research on prevention and treatment].
    Sobocki P; Allgulander C; Hillert J; Jönsson B
    Lakartidningen; 2007 May 14-29; 104(20-21):1590-4. PubMed ID: 17564267
    [No Abstract]   [Full Text] [Related]  

  • 23. The economic impact of overactive bladder syndrome in six Western countries.
    Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
    BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The costs of disorders of the brain in Switzerland: an update from the European Brain Council Study for 2010.
    Maercker A; Perkonigg A; Preisig M; Schaller K; Weller M;
    Swiss Med Wkly; 2013; 143():w13751. PubMed ID: 23297120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Estimated health care expenditures for 'demented' patients].
    Ringoir DJ; van Duuren R
    Gerontologie; 1981 Feb; 12(1):28-37. PubMed ID: 6783484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National health care costs of peripheral arterial disease in the Medicare population.
    Hirsch AT; Hartman L; Town RJ; Virnig BA
    Vasc Med; 2008 Aug; 13(3):209-15. PubMed ID: 18687757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The socio-economical burden of hypersomnia.
    Jennum P; Kjellberg J
    Acta Neurol Scand; 2010 Apr; 121(4):265-70. PubMed ID: 20047573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional variations and determinants of direct psychiatric costs in Sweden.
    Tiainen A; Edman G; Flyckt L; Tomson G; Rehnberg C
    Scand J Public Health; 2008 Jul; 36(5):483-92. PubMed ID: 18635731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The cost of illness].
    van Roijen L; Koopmanschap MA; Bonneux L
    Ned Tijdschr Geneeskd; 1992 Jan; 136(2):74-80. PubMed ID: 1732831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An estimate of the worldwide prevalence and direct costs of dementia in 2003.
    Wimo A; Jonsson L; Winblad B
    Dement Geriatr Cogn Disord; 2006; 21(3):175-81. PubMed ID: 16401889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A framework for the economic analysis of child and adolescent mental disorders.
    Hsia RY; Belfer ML
    Int Rev Psychiatry; 2008 Jun; 20(3):251-9. PubMed ID: 18569177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
    Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost of disorders of the brain in Austria in the year 2004].
    Wancata J; Sobocki P; Katschnig H;
    Wien Klin Wochenschr; 2007; 119(3-4):91-8. PubMed ID: 17347857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Driving cost factors in adult outpatients with refractory epilepsy: a daily clinical practice in clinics of neurology in Spain.
    Peña P; Sancho J; Rufo M; Martínez S; Rejas J;
    Epilepsy Res; 2009 Feb; 83(2-3):133-43. PubMed ID: 19095410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomics of subcutaneous allergen immunotherapy.
    Incorvaia C; Agostinis F; Amoroso S; Ariano R; Barbato A; Bassi M; Cadario G; Campi P; Cardinale F; Romano C; Ciprandi G; D'Anneo R; Dal Bo S; Di Gioacchino M; Fiocchi A; Galimberti M; Galli E; Giovannini M; La Grutta S; Lombardi C; Marcucci F; Marseglia GL; Mastrandrea F; Minelli M; Nettis E; Novembre E; Ortolani C; Pajno G; Piras PP; Passalacqua G; Patriarca G; Pucci S; Quercia O; Romano A; Schiavino D; Sforza M; Tosca MA; Tripodi S; Zambito M; Puccinelli P; Frati F
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():17-20. PubMed ID: 18924462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new population-based measure of the economic burden of mental illness in Canada.
    Lim KL; Jacobs P; Ohinmaa A; Schopflocher D; Dewa CS
    Chronic Dis Can; 2008; 28(3):92-8. PubMed ID: 18341763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina.
    Christensen MC; Previgliano I; Capparelli FJ; Lerman D; Lee WC; Wainsztein NA
    Acta Neurol Scand; 2009 Apr; 119(4):246-53. PubMed ID: 18771525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Modelling of the costs of productivity losses due to smoking in Germany for the year 2005].
    Prenzler A; Mittendorf T; von der Schulenburg JM
    Gesundheitswesen; 2007 Nov; 69(11):635-43. PubMed ID: 18080936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The economic burden to the public health system of treating non-viral injecting-related injury and disease in Australia (a cost of illness analysis).
    Sweeney R; Conroy AB; Dwyer R; Aitken CK
    Aust N Z J Public Health; 2009 Aug; 33(4):352-7. PubMed ID: 19689596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.